News

This segment of the latest interview with Lawrence Eichenfield, MD, features a discussion about the ICONIC-LEAD study.

The new tablet formulation of maralixibat for the treatment of cholestatic pruritus in patients with ALGS and PFIC is expected to be available in June.

In this Q&A, Augsten discusses treatment strategies, challenges, and non-pharmacological interventions for schizophrenia and bipolar I disorder based on recent survey findings.

Lafayette reflects on recent therapeutic advances in IgA nephropathy and looks ahead to other renal pipeline developments he’s looking forward to in 2025.

Anemia correction reduced perioperative rates but showed no significant impact on postoperative outcomes, emphasizing the need for prehabilitation strategies.

Erickson encouraged clinicians to get involved in advocacy for health policy issues they are passionate about.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

In this interview, Lawrence Eichenfield, MD, speaks on his team’s recent research on icotrokinra for patients with moderate-to-severe plaque psoriasis.

HCPLive spoke with Kane about new phase 2 data showing that an oral benzamide provides a significant change from baseline in CGI-S scores for participants with acute schizophrenia.

Our top 5 headlines spotlight developments in AI-driven care, diabetes tech, and dermatology, alongside key FDA actions in ophthalmology and nephrology.

Herzig discussed special considerations for treating pain in people with OUD.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Gelles discussed potential concerns with AI’s use in reducing administrative burden but stressed its promise.

Payal Kohli, MD, explores how evolving tools and strategies in lipid management are reshaping preventive cardiology.

Erickson discussed how federal travel restrictions put critical patient care and workforce stability at risk.

This analysis demonstrates the effectiveness of methotrexate application via microinfusion in frontal fibrosing alopecia.

Despite no direct correlation being identified, this research highlights a potential association between the two conditions.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

These data highlight the potential impacts of baricitinib across significant hair-bearing areas involved in alopecia areata.

Vega discussed recent efforts in the public health field and his own center that have helped to improve screening rates.

Most patients preferred OLC over their previous phosphate binder, and pill number and size were identified as barriers to phosphate binder adherence.

Tailor discusses the future of AI in ophthalmology and beyond, and some of the challenges it may bring.

Laine gave an overview of the ACP Internal Medicine’s Friday Plenary session and how it reflects top-of-mind topics for IM clinicians.

With regulatory clearance for people aged ≥18 years with diabetes, Dexcom G7 boasts the longest-lasting wearable and most accurate CGM system.